Liver damage

The Liver is a huge chemical factory that manufactures basic biochemicals that are used by our entire body. It is central to our digestion of fats, to metabolism, to detoxification and to many other vital processes. When it fails, death will typically occur within 24 hours.

Detoxification, one of the many vital functions of the Liver, is performed through multiple chemical pathways. These pathways chemically alter toxic materials into harmless substances that are water or fat soluble. The water soluble end products are sent to the Kidneys for excretion in the Urine. The fat soluble end products are sent to the small intestine for subsequent excretion.

Virtually all synthetic drugs, as well as many natural drugs and compounds, are regarded by the Liver as toxic. For this reason many, if not most, prescriptions for synthetic drugs call for up to 50 times the dosage needed to combat the symptom treated. The assumption is made that sufficient drug must be introduced into the system to overcome the detoxification activity of the Liver.

This is one of the reasons why most, if not all, modern synthetic drugs have one or more undesired side effects. Many of the Hypoglycemic agents (agents that lower blood sugar) used to treat Type II diabetes and Hyperinsulinemia are known to cause liver damage. There are so many of these agents, with more appearing every day, in an exploding drug marketplace, that it isn't possible to list and discuss them all on this web site. Some of the toxic effects of these drugs affect other organs of the body in addition to the liver. An increasingly common side effect is that they kill. In our Special Report we thoroughly discuss the common side effects of all of the current classifications of Hypoglycemic agents.

When you contemplate taking a prescripton drug it is very important to understand the consequences of these drugs. You can visit the library to look up the drug in the "Physicians Desk Reference" (PDR). Or, alternatively, if you have our Special Report you can quickly look up the risk factors involved with the medication you're taking in the appropriate section of the report. This will eneble you to determine the nature of its side effects. If you are already experiencing any of these side effects it is time to have a serious talk with your physician. We cite here side effects for a few of the commonly prescribed agents used to control blood sugar in Hyperinsulinemic and Type II diabetic patients so that you can get the idea.

The Sulfonylureas are a class of drugs that include Orinase, Tolinase, Diabinase and others. These drugs have been implicated in greatly increased deaths from Heart Disease and Hepatitis, specifically Granulomatus Hepatitis.

Glyburide, another Hypoglycemic agent has been reportedly associated with Cholestatic Jaundice, with Hepatitis and with Hypersensitivity Angitis; all of these are very serious Liver diseases.

Rezulin is an oral Hypoglycemic agent that has come to be associated with Liver Cancer. It was believed to be a potent Cancer producer by the original FDA investigating officer who refused to approve it for American use. He was administratively removed from the case and replaced by another who quickly approved it. After approval it killed an estimated 100 people before recently being finally removed from the American market by our FDA. It had previously failed to gain regulatory approval with England's equivalent of our FDA. This matter is currently headed for the courts.

In addition to drug induced Liver damage, evidence is slowly accumulating to suggest that the Hyperinsulinemia itself may cause Liver damage. High levels of Triglycerides in the blood stream are a known result produced by the development of Hyperinsulinemia and Hyperglycemia (Type II diabetes). When these Triglyceride levels become chronic, they induce a condition known as Hepatic Steatosis (fatty liver). In this condition, the Liver becomes infiltrated with Triglycerides and much of its normal function is impaired.

In our section on Hyperinsulinemia we present effective ways to deal with this disease. Below we include a starter list of references for those who wish to do further investigation. In addition to the contents of this web page, which have been designed to include the essential information needed, more information is available in our Special Report on this disease.

References:

  1. Saw D, et al, "Granulomatous hepatitis associated with glyburide.", Dig Dis Sci 1996 Feb;41(2):322-325
  2. Wanless IR, Lentz JS," Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.", Hepatology 1990 Nov;12(5):1106-1110
  3. Whitaker JM, "Reversing Diabetes.", Warner Books, Inc. 666 Fifth avenue, NY, NY. 10103

Return to home page